Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

167
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
167
Secondary Active Transport01:32

Secondary Active Transport

6.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

130
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vitro</i> and <i>in vivo</i> evaluation of DNA-integrated diclofenac-HPMC hydrogel for enhanced ocular anti-inflammatory drug delivery.

Journal of biomaterials science. Polymer edition·2026
Same author

The skin microbiome-immune-barrier axis: implications for inflammatory skin disorders and immunotherapeutic strategies.

Immunotherapy·2026
Same author

Development of HPMC-modified starch/ZnO nanocomposite films using biodegradable plasticizers for improved antioxidant, antimicrobial, and cytocompatible characteristics.

Journal of biomaterials science. Polymer edition·2026
Same author

Correction: Hepatoprotective Mechanism of Shorea Robusta Gaertn. f. Against Isoniazid-induced Hepatotoxicity by Targeting TNF-α, TGF-β1, and PPAR-α: Insights from Computational Profiling To Immunohistochemical Confirmation.

Cell biochemistry and biophysics·2026
Same author

Hepatoprotective Mechanism of Shorea Robusta Gaertn. f. Against Isoniazid-induced Hepatotoxicity by Targeting TNF-α, TGF-β1, and PPAR-α: Insights from Computational Profiling To Immunohistochemical Confirmation.

Cell biochemistry and biophysics·2026
Same author

Metallo-herb complexes as emerging therapeutics: chemistry, synthesis approaches, and pharmacological insights.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·2026

Related Experiment Video

Updated: May 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K

Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond.

Pratikeswar Panda1, Rajaram Mohapatra1, Biswajit Samantaray1

  • 1Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India.

Current Drug Research Reviews
|April 4, 2025
PubMed
Summary
This summary is machine-generated.

Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors are effective type 2 diabetes treatments with cardiovascular and renal benefits. While generally safe, potential risks like hypoglycemia and infections require careful patient monitoring.

Keywords:
SGLT2 inhibitorsdiabetic ketoacidosisfractures.hypoglycaemialower limb amputationtype 2 diabetesurinary tract infections

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.0K

Related Experiment Videos

Last Updated: May 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.0K

Area of Science:

  • Endocrinology
  • Nephrology
  • Cardiology

Background:

  • Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors represent a novel oral drug class for type 2 diabetes management.
  • These gliflozins target SGLT2 in renal proximal tubules, reducing glucose and sodium reabsorption and promoting urinary sugar excretion.
  • Beyond glycemic control, SGLT2 inhibitors exhibit pleiotropic effects beneficial for cardiac and renal function.

Purpose of the Study:

  • To provide a comprehensive safety overview of currently available SGLT2 inhibitors.
  • To summarize the known risks and benefits associated with this class of diabetes medications.

Main Methods:

  • Literature review of safety data for SGLT2 inhibitors.
  • Analysis of reported adverse events and clinical trial outcomes.

Main Results:

  • SGLT2 inhibitors demonstrate significant cardiovascular and renal protective effects.
  • Potential adverse events include hypoglycemia, urinary tract infections, diabetic ketoacidosis, lower limb amputations, and fractures.
  • While some risks are uncommon, they can have severe consequences necessitating close patient supervision.

Conclusions:

  • SGLT2 inhibitors are effective treatments for type 2 diabetes, offering substantial cardiovascular and renal protection.
  • A favorable overall safety profile exists, but careful monitoring for specific adverse events is crucial for patient safety.